Axon Enterprise, Inc $AXON Holdings Raised by Arkadios Wealth Advisors

Arkadios Wealth Advisors increased its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 90.6% during the second quarter, HoldingsChannel reports. The firm owned 3,147 shares of the biotechnology company’s stock after acquiring an additional 1,496 shares during the period. Arkadios Wealth Advisors’ holdings in Axon Enterprise were worth $2,606,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Emerald Advisers LLC boosted its holdings in shares of Axon Enterprise by 1.9% in the second quarter. Emerald Advisers LLC now owns 1,397 shares of the biotechnology company’s stock worth $1,157,000 after buying an additional 26 shares during the period. Barnes Dennig Private Wealth Management LLC purchased a new stake in shares of Axon Enterprise in the 2nd quarter valued at approximately $155,000. World Investment Advisors boosted its stake in Axon Enterprise by 35.8% in the 2nd quarter. World Investment Advisors now owns 690 shares of the biotechnology company’s stock worth $571,000 after purchasing an additional 182 shares during the period. Fairfield Financial Advisors LTD purchased a new position in Axon Enterprise during the 2nd quarter worth approximately $248,000. Finally, New York Life Investment Management LLC raised its stake in Axon Enterprise by 3.2% during the 2nd quarter. New York Life Investment Management LLC now owns 11,044 shares of the biotechnology company’s stock valued at $9,144,000 after purchasing an additional 341 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on AXON shares. Craig Hallum raised Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 target price for the company in a research report on Tuesday, August 5th. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. Raymond James Financial reaffirmed an “outperform” rating and set a $855.00 target price (up previously from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. UBS Group reiterated a “neutral” rating and issued a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Wolfe Research started coverage on shares of Axon Enterprise in a research report on Monday, July 7th. They issued an “outperform” rating for the company. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $841.64.

Axon Enterprise Stock Down 2.7%

AXON opened at $738.88 on Friday. The company has a market capitalization of $58.01 billion, a PE ratio of 182.44, a price-to-earnings-growth ratio of 29.49 and a beta of 1.41. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. Axon Enterprise, Inc has a fifty-two week low of $422.38 and a fifty-two week high of $885.91. The business has a 50-day moving average of $731.73 and a 200-day moving average of $730.58.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm’s revenue was up 32.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. Equities research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other news, CFO Brittany Bagley sold 5,000 shares of Axon Enterprise stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the completion of the sale, the chief financial officer directly owned 93,592 shares in the company, valued at $66,813,456.96. The trade was a 5.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, President Joshua Isner sold 15,919 shares of Axon Enterprise stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the sale, the president owned 238,379 shares of the company’s stock, valued at approximately $177,892,712.54. This represents a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 59,932 shares of company stock worth $45,115,616 over the last quarter. Insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.